Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Gains from Sales and Divestitures: 2020-2024

Historic Gains from Sales and Divestitures for Beam Therapeutics (BEAM) over the last 5 years, with Dec 2024 value amounting to $1.3 million.

  • Beam Therapeutics' Gains from Sales and Divestitures rose 36.25% to $783,939 in Q3 2025 from the same period last year, while for Sep 2025 it was $783,939, marking a year-over-year increase of 36.25%. This contributed to the annual value of $1.3 million for FY2024, which is 177.31% up from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Gains from Sales and Divestitures is $1.3 million, which was up 177.31% from $469,531 recorded in FY2023.
  • Over the past 5 years, Beam Therapeutics' Gains from Sales and Divestitures peaked at $1.6 million during FY2020, and registered a low of $424,303 during FY2022.
  • Its 3-year average for Gains from Sales and Divestitures is $731,957, with a median of $469,531 in 2023.
  • In the last 5 years, Beam Therapeutics' Gains from Sales and Divestitures slumped by 58.44% in 2022 and then soared by 177.31% in 2024.
  • Yearly analysis of 5 years shows Beam Therapeutics' Gains from Sales and Divestitures stood at $1.6 million in 2020, then tumbled by 37.71% to $1.0 million in 2021, then tumbled by 58.44% to $424,303 in 2022, then climbed by 10.66% to $469,531 in 2023, then surged by 177.31% to $1.3 million in 2024.